American Century Companies Inc Cerevel Therapeutics Holdings, Inc. Transaction History

American Century Companies Inc

  • $160 Billion
  • Q2 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024
BUY
$20.27 - $42.44 $8.38 Million - $17.5 Million
413,203 New
413,203 $17.5 Million
Q3 2023

Nov 13, 2023
SELL
$20.26 - $31.91 $30,471 - $47,992
-1,504 Reduced 0.49%
307,743 $6.72 Million
Q2 2023

Aug 14, 2023
BUY
$23.9 - $35.38 $1.32 Million - $1.95 Million
55,246 Added 21.75%
309,247 $9.83 Million
Q1 2023

May 11, 2023
BUY
$22.82 - $35.32 $61,089 - $94,551
2,677 Added 1.07%
254,001 $6.2 Million
Q4 2022

Feb 13, 2023
BUY
$25.35 - $31.96 $6.37 Million - $8.03 Million
251,324 New
251,324 $7.93 Million

Others Institutions Holding CERE

# of Institutions
242
Shares Held
154M
Call Options Held
2.19M
Put Options Held
3.87M
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track American Century Companies Inc Portfolio

Follow American Century Companies Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Century Companies Inc, based on Form 13F filings with the SEC.

News

Stay updated on American Century Companies Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email